RX-10100

Rexahn Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	RX-10100
Also known as	Serdaxin®, Serdaxin
Sponsor	Rexahn Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder (PHASE2)
Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD) (PHASE2)
Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RX-10100 CI brief — competitive landscape report
RX-10100 updates RSS · CI watch RSS
Rexahn Pharmaceuticals, Inc. portfolio CI